Projects per year
Personal profile
Biography
Associate Professor Yoland Antill works as a Medical Oncologist and as a Cancer Genetics specialist within the public and private sector in Melbourne with over 20 years of experience in each discipline. Her working and research interests are in the management of Breast and Gynaecological cancers together with Hereditary Cancer Syndromes. She is the current chair of ANZGOG's Uterine Tumour working Group and a member of their Research Advisory Committee. Additionally she has advisory roles with Breast Cancer Network of Australia, Ovarian Cancer Australia as well as a number of Industry related boards. Yoland is the lead investigator for a number of local and international research studies and is involved in the development and conduct of clinical and supportive care trials and has published extensively within peer review journals.
Associate Professor Yoland Antill, BMed FRACP MD
Adjunct Associate Professor, Monash University, VIC, Australia
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Research area keywords
- Medical oncology
- Hereditary cancer syndromes
- Breast cancer
- Gynaecological cancers
Network
Projects
- 4 Active
-
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)
23/05/23 → 23/05/25
Project: Research
-
A phase 3, randomised, double-blind study of Trilaciclib or placebo in patients receiving first or second line Gemcitabine and Carboplatin chemotherapy for locally advanced unresectable or metastatic triple-negative breast cancer [G1T28-208] [PRESERVE 2].
Antill, Y. & Lai, L. H.
25/11/21 → 31/12/24
Project: Research
-
A Phase 1b/III study of Ipatasertib plus Palbociclib and Fulvestrant versus placebo plus Palbociclib and Fulvestrant in hormone receptor positive and Her2 negative locally advanced unresectable or metastatic breast cancer [Ipatunity150] [CO41012]
Antill, Y., Baker, E. & Thompson, K.
13/02/20 → 31/12/25
Project: Research
-
The impact of coding germline variants on contralateral breast cancer risk and survival
Morra, A., Mavaddat, N., Muranen, T. A., Ahearn, T. U., Allen, J., Andrulis, I. L., Auvinen, P., Becher, H., Behrens, S., Blomqvist, C., Bojesen, S. E., Bolla, M. K., Brauch, H., Camp, N. J., Carvalho, S., Castelao, J. E., Cessna, M. H., Chang-Claude, J., Chenevix-Trench, G., Czene, K., & 62 others , 2 Mar 2023, In: American Journal of Human Genetics. 110, 3, p. 475-486 12 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
The role of depression and other psychological factors in work ability among breast cancer survivors in Australia
Kim, S-Y., Kissane, D. W., Richardson, G., Senior, J., Morgan, J., Gregory, P., Birks, S., Ooi, C., Lipton, L., Antill, Y., Vereker, M., Michael, N. & Bobevski, I., Feb 2022, In: Psycho-Oncology. 31, 2, p. 167-175 9 p.Research output: Contribution to journal › Article › Research › peer-review
8 Citations (Scopus) -
CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers
NBCS Collaborators, AOCS Group, ABCTB Investigators & kConFab Investigators, 16 Feb 2021, In: British Journal of Cancer. 124, 4, p. 842-854 13 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access5 Citations (Scopus) -
Mendelian randomisation study of smoking exposure in relation to breast cancer risk
Park, H. A., Neumeyer, S., Michailidou, K., Bolla, M. K., Wang, Q., Dennis, J., Ahearn, T. U., Andrulis, I. L., Anton-Culver, H., Antonenkova, N. N., Arndt, V., Aronson, K. J., Augustinsson, A., Baten, A., Beane Freeman, L. E., Becher, H., Beckmann, M. W., Behrens, S., Benitez, J., Bermisheva, M., & 106 others , 12 Oct 2021, In: British Journal of Cancer. 125, 8, p. 1135-1145 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access3 Citations (Scopus) -
Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses
Kang, E. Y., Cheasley, D., LePage, C., Wakefield, M. J., da Cunha Torres, M., Rowley, S., Salazar, C., Xing, Z., Allan, P. E., Bowtell, D. D. L., Mes-Masson, A. M., Provencher, D. M., Rahimi, K., Kelemen, L. E., Fasching, P. A., Doherty, J. A., Goodman, M. T., Goode, E. L., Deen, S., Pharoah, P. D. P., & 25 others , Jan 2021, In: Modern Pathology. 34, 1, p. 194-206 13 p.Research output: Contribution to journal › Article › Research › peer-review
13 Citations (Scopus)